From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
2-(2-Hydroxybenzoyl)oxybenzoic acid
Clinical data
Trade names Disalcid, Salflex
AHFS/ monograph
MedlinePlus a682880
  • US: C (Risk not ruled out)
Legal status
CAS Registry Number 552-94-3 YesY
ATC code N02BA06
PubChem CID: 5161
DrugBank DB01399 YesY
ChemSpider 4977 N
KEGG D00428 N
Chemical data
Formula C14H10O5
Molecular mass 258.23 g/mol
 N (what is this?)  (verify)

Salsalate is a medication that belongs to the salicylate and non-steroidal anti-inflammatory drug (NSAID) classes. Relative to other NSAIDs, salsalate has a weak inhibitory effect on the cyclooxygenase enzyme and decreases the production of several proinflammatory chemical signals such as interleukin-6, TNF-alpha, and C-reactive protein.[1] The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition of NF-κB.[1][2] Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[3]


Common conditions in which salsalate may be indicated include inflammatory disorders such as rheumatoid arthritis or noninflammatory disorders such as osteoarthritis.[1][4]


Salsalate has been proposed for the prevention and treatment of type 2 diabetes mellitus due to its ability to lower insulin resistance associated with inflammation and may be useful in prediabetes.[1] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[1]


Salsalate had been suggested as possible treatment for diabetes as early as 1876.[1][5][6]


  1. ^ a b c d e f Anderson K, Wherle L, Park M, Nelson K, Nguyen L (June 2014). "Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies". Am Health Drug Benefits 7 (4): 231–5. PMC 4105730. PMID 25126374. 
  2. ^ Ridker PM, Lüscher TF (July 2014). "Anti-inflammatory therapies for cardiovascular disease". Eur Heart Journal 35 (27): 1782–91. doi:10.1093/eurheartj/ehu203. PMC 4155455. PMID 24864079. 
  3. ^ Salsalate entry
  4. ^ Hardie DG (July 2013). "AMPK: a target for drugs and natural products with effects on both diabetes and cancer". Diabetes 62 (7): 2164–72. doi:10.2337/db13-0368. PMC 3712072. PMID 23801715. 
  5. ^ Kendall Powell (May 31, 2007). "The Two Faces of Fat". Nature 447 (7144): 525–7. doi:10.1038/447525a. PMID 17538594. 
  6. ^ Ebstein, W (1876). "Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben". Berliner Klinische Wochenschrift 13: 337–340.